Skip to main content
Back
RCUS logo

Arcus Biosciences, Inc.

Data quality: 100%
RCUS
NYSE Healthcare Biotechnology
$21.41
▼ $0.23 (-1.06%)
Mkt Cap: 2.16B
Day Range
$21.23 $22.29
52-Week Range
$6.50 $26.40
Volume
585,668
50D / 200D Avg
$21.61 / $16.52
Prev Close
$21.64

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E -6.1 0.4
P/B 3.4 2.9
ROE % -63.3 3.8
Net Margin % -142.9 3.9
Rev Growth 5Y % -10.4 10.0
D/E 0.2 0.2

Analyst Price Target

Hold
$28.00 +30.8%
Low: $20.00 High: $35.00
Forward EPS
-$3.81
Est. Revenue
93 M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $1.70
$0.09 – $4.24
970 M 6
FY2029 -$0.77
-$1.93 – -$0.04
490 M 6
FY2028 -$2.19
-$2.83 – -$1.43
220 M 8

Key Takeaways

Revenue declined -10.39% annually over 5 years
Debt/Equity of 0.16 — conservative balance sheet
Negative free cash flow of -484.00M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 6.13%
Capital efficient — spends only 0.81% of revenue on capex

Growth

Revenue Growth (5Y)
-10.39%
Revenue (1Y)-4.26%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-63.26%
ROIC-39.66%
Net Margin-142.91%
Op. Margin-156.28%

Safety

Debt / Equity
0.16
Current Ratio4.36
Interest Coverage-48.25

Valuation

P/E Ratio
-6.11
P/B Ratio3.42
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -4.26% Revenue Growth (3Y) 45.30%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -10.39% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 247.00M Net Income (TTM) -353.00M
ROE -63.26% ROA -30.99%
Gross Margin 95.95% Operating Margin -156.28%
Net Margin -142.91% Free Cash Flow (TTM) -484.00M
ROIC -39.66% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.16 Current Ratio 4.36
Interest Coverage -48.25 Dividend Yield 0.00%
Valuation
P/E Ratio -6.11 P/B Ratio 3.42
P/S Ratio 8.73 PEG Ratio -1.52
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 2.16B Enterprise Value 2.03B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 247.00M 258.00M 117.00M 112.00M 383.00M
Net Income -353.00M -283.00M -307.00M -267.00M 53.00M
EPS (Diluted) -3.29 -3.14 -4.15 -3.71 0.71
Gross Profit 237.00M 258.00M 117.00M 112.00M 383.00M
Operating Income -386.00M -330.00M -340.00M -280.00M 54.00M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.14B 1.15B 1.10B 1.35B 1.59B
Total Liabilities 508.00M 665.00M 633.00M 688.00M 750.45M
Shareholders' Equity 631.00M 485.00M 462.00M 657.00M 841.45M
Total Debt 99.00M 60.00M 11.00M 120.00M 121.99M
Cash & Equivalents 222.00M 150.00M 127.00M 206.00M 147.91M
Current Assets 1.01B 1.02B 831.00M 1.07B 1.26B
Current Liabilities 231.00M 226.00M 184.00M 193.00M 166.08M